112 related articles for article (PubMed ID: 3947382)
1. Adriamycin accumulation and metabolism in adriamycin-sensitive and -resistant human ovarian cancer cell lines.
Louie KG; Hamilton TC; Winker MA; Behrens BC; Tsuruo T; Klecker RW; McKoy WM; Grotzinger KR; Myers CE; Young RC
Biochem Pharmacol; 1986 Feb; 35(3):467-72. PubMed ID: 3947382
[TBL] [Abstract][Full Text] [Related]
2. Radiation survival parameters of antineoplastic drug-sensitive and -resistant human ovarian cancer cell lines and their modification by buthionine sulfoximine.
Louie KG; Behrens BC; Kinsella TJ; Hamilton TC; Grotzinger KR; McKoy WM; Winker MA; Ozols RF
Cancer Res; 1985 May; 45(5):2110-5. PubMed ID: 3986765
[TBL] [Abstract][Full Text] [Related]
3. Potentiation of melphalan cytotoxicity in human ovarian cancer cell lines by glutathione depletion.
Green JA; Vistica DT; Young RC; Hamilton TC; Rogan AM; Ozols RF
Cancer Res; 1984 Nov; 44(11):5427-31. PubMed ID: 6488194
[TBL] [Abstract][Full Text] [Related]
4. Electrochemical monitoring of anticancer compounds on the human ovarian carcinoma cell line A2780 and its adriamycin- and Cisplatin-resistant variants.
Woolley DE; Tetlow LC; Adlam DJ; Gearey D; Eden RD; Ward TH; Allen TD
Exp Cell Res; 2002 Feb; 273(1):65-72. PubMed ID: 11795947
[TBL] [Abstract][Full Text] [Related]
5. [Establishment of adriamycin-resistant human ovarian carcinoma cell line and its mechanism of multidrug resistance].
Li PY; Lin C
Yao Xue Xue Bao; 1995; 30(4):258-62. PubMed ID: 7660793
[TBL] [Abstract][Full Text] [Related]
6. Collateral susceptibility of adriamycin-, melphalan- and cisplatin-resistant human ovarian tumor cells to bleomycin.
Tsuruo T; Hamilton TC; Louie KG; Behrens BC; Young RC; Ozols RF
Jpn J Cancer Res; 1986 Sep; 77(9):941-5. PubMed ID: 2429947
[TBL] [Abstract][Full Text] [Related]
7. Accumulation of anthracenyl-amino acid topoisomerase I and II inhibitors in drug-sensitive and drug-resistant human ovarian cancer cell lines determined by high-performance liquid chromatography.
Cummings J; Meikle I; Macpherson JS; Smyth JF
Cancer Chemother Pharmacol; 1995; 37(1-2):103-9. PubMed ID: 7497578
[TBL] [Abstract][Full Text] [Related]
8. Cooperativity between free and N-(2-hydroxypropyl) methacrylamide copolymer bound adriamycin and meso-chlorin e6 monoethylene diamine induced photodynamic therapy in human epithelial ovarian carcinoma in vitro.
Lu JM; Peterson CM; Guo-Shiah J; Gu ZW; Peterson CA; Straight RC; Kopecek J
Int J Oncol; 1999 Jul; 15(1):5-16. PubMed ID: 10375588
[TBL] [Abstract][Full Text] [Related]
9. Augmentation of adriamycin, melphalan, and cisplatin cytotoxicity in drug-resistant and -sensitive human ovarian carcinoma cell lines by buthionine sulfoximine mediated glutathione depletion.
Hamilton TC; Winker MA; Louie KG; Batist G; Behrens BC; Tsuruo T; Grotzinger KR; McKoy WM; Young RC; Ozols RF
Biochem Pharmacol; 1985 Jul; 34(14):2583-6. PubMed ID: 4040369
[No Abstract] [Full Text] [Related]
10. Reversal of adriamycin resistance by verapamil in human ovarian cancer.
Rogan AM; Hamilton TC; Young RC; Klecker RW; Ozols RF
Science; 1984 Jun; 224(4652):994-6. PubMed ID: 6372095
[TBL] [Abstract][Full Text] [Related]
11. Rapid distribution of adriamycin in the ascitic and pleural fluid of women with ovarian carcinomas.
Lazo JS; Schwartz PE
Gynecol Oncol; 1985 May; 21(1):65-72. PubMed ID: 3988127
[TBL] [Abstract][Full Text] [Related]
12. A close association of adriamycin resistance with expression of cell surface antigens in adriamycin-resistant cell lines of herpes simplex virus type 2-transformed Syrian hamster cells.
Kimura S; Okazaki K
Jpn J Cancer Res; 1985 Dec; 76(12):1179-85. PubMed ID: 3005209
[TBL] [Abstract][Full Text] [Related]
13. Changes in cellular glutathione content during adriamycin treatment in human ovarian cancer--a possible indicator of chemosensitivity.
Lee FY; Siemann DW; Sutherland RM
Br J Cancer; 1989 Sep; 60(3):291-8. PubMed ID: 2789934
[TBL] [Abstract][Full Text] [Related]
14. Resistance to adriamycin: relationship of cytotoxicity to drug uptake and DNA single- and double-strand breakage in cloned cell lines of adriamycin-sensitive and -resistant P388 leukemia.
Goldenberg GJ; Wang H; Blair GW
Cancer Res; 1986 Jun; 46(6):2978-83. PubMed ID: 3698020
[TBL] [Abstract][Full Text] [Related]
15. Sequential emergence of distinct resistance phenotypes in murine erythroleukemia cells under adriamycin selection: decreased anthracycline uptake precedes increased P-glycoprotein expression.
Slapak CA; Daniel JC; Levy SB
Cancer Res; 1990 Dec; 50(24):7895-901. PubMed ID: 1979251
[TBL] [Abstract][Full Text] [Related]
16. Effect of lung resistance-related protein on the resistance to cisplatin in human ovarian cancer cell lines.
Wang W; Ke S; Chen G; Gao Q; Wu S; Wang S; Zhou J; Yang X; Lu Y; Ma D
Oncol Rep; 2004 Dec; 12(6):1365-70. PubMed ID: 15547764
[TBL] [Abstract][Full Text] [Related]
17. Pharmacologic reversal of drug resistance in ovarian cancer.
Ozols RF
Semin Oncol; 1985 Sep; 12(3 Suppl 4):7-11. PubMed ID: 4048979
[TBL] [Abstract][Full Text] [Related]
18. Experimental models for the study of drug resistance in osteosarcoma: P-glycoprotein-positive, murine osteosarcoma cell lines.
Takeshita H; Gebhardt MC; Springfield DS; Kusuzaki K; Mankin HJ
J Bone Joint Surg Am; 1996 Mar; 78(3):366-75. PubMed ID: 8613443
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of human ovarian cancer colony formation by adriamycin and its major metabolites.
Ozols RF; Willson JK; Weltz MD; Grotzinger KR; Myers CE; Young RC
Cancer Res; 1980 Nov; 40(11):4109-12. PubMed ID: 7471054
[TBL] [Abstract][Full Text] [Related]
20. A simple fluorometric method to discriminate adriamycin-resistant subline from adriamycin-sensitive parental P388 murine leukemia cell line.
Dekker K; Kojima N; Yamamoto S; Tatsumi K; Mino M; Yagi K
Biochem Int; 1987 Jun; 14(6):997-1001. PubMed ID: 3453100
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
